https://www.selleckchem.com/pr....oducts/rg2833-rgfp10
Forty-one (78.85%) and 49 (94.23%) patients achieved visual acuity equal to or better than 20/40 and 20/200, respectively, at the third-month follow-up visit as compared to eight (15.38%) and 13 (25%) patients, respectively, at presentation (P 0.05). In addition, mean LogMAR visual acuity at the time of presentation was 0.755 which improved to 0.307 at the third-month follow-up visit (P 0.05). None of the patients developed hypersensitivity reactions to intravitreal moxifloxacin. Intravitreal moxifloxacin injections sho